Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/11629
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Chua, Horng-Ruey | en |
dc.contributor.author | Baldwin, Ian C | en |
dc.contributor.author | Ho, Lisa | en |
dc.contributor.author | Collins, Allison L | en |
dc.contributor.author | Allsep, Helen | en |
dc.contributor.author | Bellomo, Rinaldo | en |
dc.date.accessioned | 2015-05-16T01:14:44Z | |
dc.date.available | 2015-05-16T01:14:44Z | |
dc.date.issued | 2012-12-12 | en |
dc.identifier.citation | Blood Purification 2012; 34(3-4): 306-12 | en |
dc.identifier.govdoc | 23235269 | en |
dc.identifier.other | PUBMED | en |
dc.identifier.uri | https://ahro.austin.org.au/austinjspui/handle/1/11629 | en |
dc.description.abstract | To examine biochemical effects of phosphate-containing replacement fluid (Phoxilium(®)) for continuous venovenous hemofiltration (CVVH).Retrospective comparison of respective serum biochemistry with sequential use of Accusol™ and Phoxilium, each over 48 h of CVVH.We studied 15 critically ill patients. Accusol was switched to Phoxilium after 5 (4-8) days of CVVH. Respective serum biochemistry after 36-42 h of Accusol versus Phoxilium were: phosphate 1.02 (0.82-1.15) versus 1.44 (1.23-1.78) mmol/l, ionized calcium 1.28 (1.22-1.32) versus 1.12 (1.06-1.21) mmol/l, bicarbonate 24 (23-25) versus 20 (19-22) mmol/l, base excess 0 (-2 to 1) versus -4 (-6 to -3) mmol/l (p < 0.001). Cumulative phosphate intakes during respective periods were 69.6 (56.6-76.6) versus 67.2 (46.6-79.0) mmol (p = 0.45). Plasma strong ion differences were narrower with Phoxilium (p < 0.05), with similar strong ion gaps. No additional intravenous phosphate was given during Phoxilium use. Seven patients had serum phosphate >1.44 mmol/l.Phoxilium versus Accusol use during CVVH effectively prevented hypophosphatemia but contributed to mild hyperphosphatemia, and is associated with relative hypocalcemia and metabolic acidosis. | en |
dc.language.iso | en | en |
dc.subject.other | APACHE | en |
dc.subject.other | Acute Kidney Injury.blood.complications.therapy | en |
dc.subject.other | Aged | en |
dc.subject.other | Electrolytes.blood.chemistry | en |
dc.subject.other | Female | en |
dc.subject.other | Hemodialysis Solutions.chemistry | en |
dc.subject.other | Hemofiltration.adverse effects.methods | en |
dc.subject.other | Humans | en |
dc.subject.other | Hypophosphatemia.etiology.prevention & control | en |
dc.subject.other | Intensive Care Units | en |
dc.subject.other | Male | en |
dc.subject.other | Middle Aged | en |
dc.subject.other | Phosphates.blood.chemistry | en |
dc.subject.other | Retrospective Studies | en |
dc.subject.other | Time Factors | en |
dc.title | Biochemical effects of phosphate-containing replacement fluid for continuous venovenous hemofiltration. | en |
dc.type | Journal Article | en |
dc.identifier.journaltitle | Blood Purification | en |
dc.identifier.affiliation | Department of Intensive Care, Austin Health, Heidelberg, Victoria, Australia | en |
dc.identifier.doi | 10.1159/000345343 | en |
dc.description.pages | 306-12 | en |
dc.relation.url | https://pubmed.ncbi.nlm.nih.gov/23235269 | en |
dc.type.austin | Journal Article | en |
local.name.researcher | Baldwin, Ian C | |
item.openairetype | Journal Article | - |
item.cerifentitytype | Publications | - |
item.grantfulltext | none | - |
item.fulltext | No Fulltext | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.languageiso639-1 | en | - |
crisitem.author.dept | Intensive Care | - |
crisitem.author.dept | Institute for Breathing and Sleep | - |
crisitem.author.dept | Intensive Care | - |
crisitem.author.dept | Data Analytics Research and Evaluation (DARE) Centre | - |
Appears in Collections: | Journal articles |
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.